Get the Stockscreener App
31.03
5.76%
1.69
After Hours:
31.03
Stoke Therapeutics Inc stock is traded at $31.03, with a volume of 475.68K.
It is up +5.76% in the last 24 hours and down -8.82% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$29.34
Open:
$29.5
24h Volume:
475.68K
Relative Volume:
0.67
Market Cap:
$1.93B
Revenue:
$32.08M
Net Income/Loss:
$-169.77M
P/E Ratio:
-10.92
EPS:
-2.8418
Net Cash Flow:
$-147.70M
1W Performance:
+3.57%
1M Performance:
-8.82%
6M Performance:
-0.58%
1Y Performance:
+231.52%
1-Day Range:
$29.39
$31.13
1-Week Range:
$29.18
$31.13
52-Week Range:
$9.09
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.03 | 1.83B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-05-26 | Initiated | Guggenheim | Buy |
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Nathan Lee Starts New Role as Vice President, Commercial Manufacturing at Stoke Therapeutics - hrtoday.in
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed - simplywall.st
Zorevunersen tied to long-term benefits in Dravet syndrome - Dravet Syndrome News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 - BioSpace
Lynx1 (STOK) files 13G/A reporting 4.76M shares, 8.1% stake - Stock Titan
Technical Reactions to STOK Trends in Macro Strategies - Stock Traders Daily
Stoke Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Lynx1 Capital discloses 4.12M shares of Stoke Therapeutics (STOK) - Stock Titan
Redmile Group reports 4.16M shares in Stoke Therapeutics (STOK) - Stock Titan
TD Bank (NASDAQ: STOK) reports 3.18M shares, 5.4% stake - Stock Titan
RTW Funds and R. Wong report 9.99% stake in Stoke Therapeutics (STOK) - Stock Titan
Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK) - Stock Titan
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate - Moomoo
HC Wainwright Analysts Boost Earnings Estimates for STOK - MarketBeat
Stoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balance - MSN
Stoke Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-05-11 - Seeking Alpha
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Stoke Therapeutics' (STOK) "Buy" Rating Reiterated at BTIG Research - MarketBeat
STOK Reiterates by BTIG -- Price Target Maintained at $39.00 - GuruFocus
Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60 - Moomoo
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60 - Moomoo
Stoke Therapeutics Q1 Earnings Call Highlights - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Stoke Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
Transcript : Stoke Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Stoke Therapeutics Q1 2026 slides show zorevunersen Phase 3 progress By Investing.com - Investing.com Canada
Earnings call transcript: Stoke Therapeutics Q1 2026 results show mixed performance By Investing.com - Investing.com South Africa
Earnings call transcript: Stoke Therapeutics Q1 2026 results show mixed performance - Investing.com Nigeria
Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion - ChartMill
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Why Stoke Therapeutics Stock Is Sliding Hard Today - TipRanks
STOKE THERAPEUTICS Q1 EPS USD -0.79 - Moomoo
Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q1 Revenue $6.2M, vs. FactSet Est of $6.5M - marketscreener.com
Stoke Therapeutics (Nasdaq: STOK) Q1 2026 loss, zorevunersen data and cash runway to 2028 - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) swings to Q1 2026 loss as Biogen upfront revenue rolls off - Stock Titan
Stoke Therapeutics faces earnings test after revenue miss By Investing.com - Investing.com Nigeria
Stoke Therapeutics faces earnings test after revenue miss - Investing.com UK
Trading the Move, Not the Narrative: (STOK) Edition - Stock Traders Daily
Privium Fund Management B.V. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 2,243 shares in open-market trade - Stock Titan
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):